Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

Hye Jin Choi, Byoung Chul Cho, Sang Joon Shin, Seong Ha Cheon, Jong Yul Jung, Joon Chang, Se Kyu Kim, Joo Hyuk Sohn, Joo Hang Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. Patients and methods: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m 2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. Results: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5%) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7%) and infection in three patients (13.0%). There was one treatment-related death due to pneumonia. Conclusion: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume61
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

irinotecan
Topotecan
Salvaging
Salvage Therapy
Chemotherapy
Small Cell Lung Carcinoma
Etoposide
Platinum
Refractory materials
Toxicity
Cells
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Choi, Hye Jin ; Cho, Byoung Chul ; Shin, Sang Joon ; Cheon, Seong Ha ; Jung, Jong Yul ; Chang, Joon ; Kim, Se Kyu ; Sohn, Joo Hyuk ; Kim, Joo Hang. / Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 61, No. 2. pp. 309-313.
@article{97b282819c8f46de9dca8125f8887c07,
title = "Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy",
abstract = "Purpose: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. Patients and methods: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m 2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. Results: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9{\%}) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5{\%}) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4{\%} (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7{\%}. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3{\%}) and 12 (52.2{\%}) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7{\%}) and infection in three patients (13.0{\%}). There was one treatment-related death due to pneumonia. Conclusion: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum.",
author = "Choi, {Hye Jin} and Cho, {Byoung Chul} and Shin, {Sang Joon} and Cheon, {Seong Ha} and Jung, {Jong Yul} and Joon Chang and Kim, {Se Kyu} and Sohn, {Joo Hyuk} and Kim, {Joo Hang}",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s00280-007-0505-9",
language = "English",
volume = "61",
pages = "309--313",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. / Choi, Hye Jin; Cho, Byoung Chul; Shin, Sang Joon; Cheon, Seong Ha; Jung, Jong Yul; Chang, Joon; Kim, Se Kyu; Sohn, Joo Hyuk; Kim, Joo Hang.

In: Cancer Chemotherapy and Pharmacology, Vol. 61, No. 2, 01.02.2008, p. 309-313.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

AU - Choi, Hye Jin

AU - Cho, Byoung Chul

AU - Shin, Sang Joon

AU - Cheon, Seong Ha

AU - Jung, Jong Yul

AU - Chang, Joon

AU - Kim, Se Kyu

AU - Sohn, Joo Hyuk

AU - Kim, Joo Hang

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. Patients and methods: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m 2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. Results: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5%) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7%) and infection in three patients (13.0%). There was one treatment-related death due to pneumonia. Conclusion: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum.

AB - Purpose: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. Patients and methods: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1 mg/m2 (day 1-5) and etoposide 80 mg/m 2 (day 1-3). Treatment was repeated every 21 days for a maximum of 6 cycles. Results: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0-1 in 13 (56.5%) patients. The median cycles of chemotherapy was three. Twenty-one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. Two sensitive case patients and two refractory case patients achieved partial response. After a median follow-up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in two patients (8.7%) and infection in three patients (13.0%). There was one treatment-related death due to pneumonia. Conclusion: This salvage regimen showed modest efficacy and manageable toxicities. Further study will be required in recurrent SCLC patients pretreated irinotecan and platinum.

UR - http://www.scopus.com/inward/record.url?scp=36349008662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349008662&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0505-9

DO - 10.1007/s00280-007-0505-9

M3 - Article

C2 - 17576560

AN - SCOPUS:36349008662

VL - 61

SP - 309

EP - 313

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -